.png){kind=icon}
返回
SPPARM alpha: the Lazarus effect
.png){kind=icon}
PRE
AI
DOI：10.1097/MOL.0000000000000640.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Purpose of review Atherogenic dyslipidaemia, characterized by high plasma triglycerides (a surrogate for triglyceride-rich remnant lipoproteins) and low high-density lipoprotein cholesterol (HDL-C), is prevalent in patients with type 2 diabetes mellitus (T2DM) and contributes to a high modifiable residual cardiovascular risk. Fibrates are effective in managing hypertriglyceridaemia but lack consistent cardiovascular benefit in clinical trials and exhibit pharmacokinetic interaction with statins (gemfibrozil) and renal and hepatic safety issues (fenofibrate). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha) paradigm offers potential for improving potency, selectivity and the benefit-risk profile. Recent findings The present review discusses evidence for the novel SPPARM alpha agonist, pemafibrate. Clinical trials showed robust lowering of triglyceride-rich lipoproteins, elevation in HDL-C and nonlipid beneficial effects including anti-inflammatory activity. There was a favourable safety profile, with no increase in serum creatinine, evident with fenofibrate, and improved renal and hepatic safety. The cardiovascular outcomes study PROMINENT is critical to confirming the SPPARMa concept by validating reduction in residual cardiovascular risk in patients with T2DM and long-term safety. Summary SPPARM alpha offers a new paradigm for reducing residual cardiovascular risk in T2DM. PROMINENT will be critical to differentiating the first SPPARMa, pemafibrate, as a novel therapeutic class distinct from current fibrates.
Keyword:
atherogenic dyslipidaemia
fibrate
PROMINENT Trial
remnants
selective peroxisome proliferator-activated receptor alpha modulator
SPPARM alpha
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
4.6
论文数:
2.3K
被引数:
3.9K
机构
引用论文
Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population.png)
ANNALS OF NEUROLOGY
OAAI
ANNALS OF NEUROLOGYIF7.7
OAAI分享收藏The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosisATHEROSCLEROSIS
ATHEROSCLEROSISIF5.7
PREAI
分享收藏Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatmentsGenetica
GeneticaIF0
PREAI
分享收藏
查看更多内容